文献速递妇科

老年卵巢癌、原发腹膜癌或输卵管癌患者的化疗完成情况——一项NRG肿瘤学/妇科肿瘤组研究

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
PubMed 文献 · Gynecol Oncol · 2017-01-13

研究前瞻性纳入212例年龄≥70岁的卵巢癌、原发腹膜癌或输卵管癌患者,由患者与医生共同选择卡铂+紫杉醇(CP)或卡铂单药(C)方案。基线IADL评分与完成4周期化疗(无论是否减量或延迟)相关(p=0.008),且每多一项独立活动,3级及以上毒性风险降低17%(OR 0.83,95%CI 0.72-0.96,p=0.013)。基线IADL评分与完成4周期化疗且无减量或延迟无关(p=0.21)。

要点

  • 基线IADL评分越高(越独立),完成4周期化疗的可能性越大(p=0.008)。
  • 每多一项独立活动,3级及以上毒性风险降低17%(OR 0.83,95%CI 0.72-0.96,p=0.013)。
  • 基线IADL评分与完成4周期化疗且无减量或延迟无关(p=0.21)。

核心结论

  • 基线IADL评分较高的患者更可能完成4周期化疗,且发生3级及以上毒性的可能性更低。

研究设计与样本

  • 前瞻性研究纳入212例年龄≥70岁的卵巢癌、原发腹膜癌或输卵管癌患者,由患者与医生共同选择CP方案(卡铂AUC 5,紫杉醇135mg/m2)或C方案(卡铂AUC 5),每3周给药,可在初次手术后或作为新辅助化疗(NACT)给予,并在基线、第3周期前和第4周期后完成IADL和生活质量评估。

主要发现

  • 选择CP方案的患者基线IADL评分较高(p<0.001)。
  • 调整年龄和PS后,基线IADL评分与方案选择独立相关(p=0.035)。
  • 基线IADL评分与完成4周期化疗且无减量或延迟无关(p=0.21)。
  • 基线IADL评分与完成4周期化疗(无论是否减量或延迟)相关(p=0.008)。
  • 每多一项独立活动,3级及以上毒性风险的OR为0.83(95%CI 0.72-0.96;p=0.013)。

关键数值与推荐

  • CP方案:卡铂AUC 5,紫杉醇135mg/m2,每3周一次。
  • C方案:卡铂AUC 5,每3周一次。
  • 每多一项独立活动,3级及以上毒性风险的OR为0.83(95%CI 0.72-0.96;p=0.013)。
  • 基线IADL评分与完成4周期化疗(无论是否减量或延迟)相关(p=0.008)。
  • 基线IADL评分与完成4周期化疗且无减量或延迟无关(p=0.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemotherapy without dose reductions or >7days delay in elderly ovarian cancer patients. PATIENTS AND METHODS: Patients' age ≥70 along with their physicians chose between two regimens: CP (Carboplatin AUC 5, Paclitaxel 135mg/m2) or C (Carboplatin AUC 5), both given every 3weeks either after primary surgery or as neoadjuvant chemotherapy (NACT) with IADL and quality of life assessments performed at baseline, pre-cycle 3, and post-cycle 4. RESULTS: Two-hundred-twelve women were enrolled, 152 selecting CP and 60 selecting C. Those who selected CP had higher baseline IADL scores (p<0.001). After adjusting for age and PS, baseline IADL was independently associated with the choice of regimen (p=0.035). The baseline IADL score was not found to be associated with completion of 4 cycles of chemotherapy without dose reduction or delays (p=0.21), but was associated with completion of 4 cycles of chemotherapy regardless of dose reduction and delay (p=0.008) and toxicity, with the odds ratio (OR) of grade 3+ toxicity decreasing 17% (OR: 0.83; 95%CI: 0.72-0.96; p=0.013) for each additional activity in which the patient was independent. After adjustment for chemotherapy regimen, IADL was also associated with overall survival (p=0.019) for patients receiving CP. CONCLUSION: Patients with a higher baseline IADL score (more independent) were more likely to complete 4 cycles of chemotherapy and less likely to experience grade 3 or higher toxicity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. von Gruenigen VE, Huang HQ, Beumer JH, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017. PMID: 28089376. doi:10.1016/j.ygyno.2016.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。